Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria.
Gansane A, Lingani M, Yeka A, Nahum A, Bouyou-Akotet M, Mombo-Ngoma G, Kaguthi G, Barceló C, Laurijssens B, Cantalloube C, Macintyre F, Djeriou E, Jessel A, Bejuit R, Demarest H, Marrast AC, Debe S, Tinto H, Kibuuka A, Nahum D, Mawili-Mboumba DP, Zoleko-Manego R, Mugenya I, Olewe F, Duparc S, Ogutu B. Gansane A, et al. Malar J. 2023 Jan 3;22(1):2. doi: 10.1186/s12936-022-04420-2. Malar J. 2023. PMID: 36597076 Free PMC article. Clinical Trial.
Population pharmacokinetics of artesunate and amodiaquine in African children.
Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansané A, Simpson JA, Morgan CC, White NJ, Kiechel JR. Stepniewska K, et al. Among authors: gansane a. Malar J. 2009 Aug 20;8:200. doi: 10.1186/1475-2875-8-200. Malar J. 2009. PMID: 19691851 Free PMC article. Clinical Trial.
Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, Yaro JB, Ouédraogo E, Gansané A, Bougouma EC, Konaté AT, Kaboré Y, Traoré A, Chilengi R, Soulama I, Luty AJ, Druilhe P, Cousens S, Nébié I. Sirima SB, et al. Among authors: gansane a. PLoS One. 2009 Oct 26;4(10):e7549. doi: 10.1371/journal.pone.0007549. PLoS One. 2009. PMID: 19855847 Free PMC article. Clinical Trial.
Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood BM, Diallo DA. Konaté AT, et al. Among authors: gansane a. PLoS One. 2011;6(8):e23391. doi: 10.1371/journal.pone.0023391. Epub 2011 Aug 12. PLoS One. 2011. PMID: 21858097 Free PMC article. Clinical Trial.
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.
Ouédraogo A, Tiono AB, Kargougou D, Yaro JB, Ouédraogo E, Kaboré Y, Kangoye D, Bougouma EC, Gansane A, Henri N, Diarra A, Sanon S, Soulama I, Konate AT, Watson NL, Brown V, Hendriks J, Pau MG, Versteege I, Wiesken E, Sadoff J, Nebie I, Sirima SB. Ouédraogo A, et al. Among authors: gansane a. PLoS One. 2013 Nov 11;8(11):e78679. doi: 10.1371/journal.pone.0078679. eCollection 2013. PLoS One. 2013. PMID: 24244339 Free PMC article. Clinical Trial.
34 results